X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES DR. REDDYS LAB JUBILANT LIFE SCIENCES/
DR. REDDYS LAB
 
P/E (TTM) x 19.9 26.6 75.0% View Chart
P/BV x 4.2 2.7 154.8% View Chart
Dividend Yield % 0.4 1.0 41.5%  

Financials

 JUBILANT LIFE SCIENCES   DR. REDDYS LAB
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
DR. REDDYS LAB
Mar-16
JUBILANT LIFE SCIENCES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1874,383 4.3%   
Low Rs652,750 2.4%   
Sales per share (Unadj.) Rs364.3920.1 39.6%  
Earnings per share (Unadj.) Rs6.8126.1 5.4%  
Cash flow per share (Unadj.) Rs24.5183.0 13.4%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %2.40.6 424.8%  
Book value per share (Unadj.) Rs164.9685.8 24.0%  
Shares outstanding (eoy) m159.28170.61 93.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.9 8.9%   
Avg P/E ratio x18.428.3 65.1%  
P/CF ratio (eoy) x5.119.5 26.4%  
Price / Book Value ratio x0.85.2 14.7%  
Dividend payout %43.815.9 276.3%   
Avg Mkt Cap Rs m20,061608,481 3.3%   
No. of employees `0006.221.7 28.5%   
Total wages/salary Rs m11,05231,874 34.7%   
Avg. sales/employee Rs Th9,383.07,244.4 129.5%   
Avg. wages/employee Rs Th1,786.91,470.9 121.5%   
Avg. net profit/employee Rs Th176.3992.8 17.8%   
INCOME DATA
Net Sales Rs m58,034156,978 37.0%  
Other income Rs m1912,693 7.1%   
Total revenues Rs m58,224159,671 36.5%   
Gross profit Rs m5,78634,587 16.7%  
Depreciation Rs m2,8129,705 29.0%   
Interest Rs m3,237824 392.9%   
Profit before tax Rs m-7226,751 -0.3%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6965,237 13.3%   
Profit after tax Rs m1,09021,514 5.1%  
Gross profit margin %10.022.0 45.3%  
Effective tax rate %-965.919.6 -4,933.8%   
Net profit margin %1.913.7 13.7%  
BALANCE SHEET DATA
Current assets Rs m29,280118,201 24.8%   
Current liabilities Rs m38,91268,368 56.9%   
Net working cap to sales %-16.631.7 -52.3%  
Current ratio x0.81.7 43.5%  
Inventory Days Days8460 140.6%  
Debtors Days Days5197 52.3%  
Net fixed assets Rs m55,71272,265 77.1%   
Share capital Rs m155853 18.1%   
"Free" reserves Rs m20,968111,548 18.8%   
Net worth Rs m26,265117,009 22.4%   
Long term debt Rs m17,16910,690 160.6%   
Total assets Rs m88,606200,104 44.3%  
Interest coverage x1.033.5 2.9%   
Debt to equity ratio x0.70.1 715.5%  
Sales to assets ratio x0.70.8 83.5%   
Return on assets %4.911.2 43.8%  
Return on equity %4.218.4 22.6%  
Return on capital %11.621.6 53.6%  
Exports to sales %37.846.3 81.7%   
Imports to sales %16.59.0 184.2%   
Exports (fob) Rs m21,93372,618 30.2%   
Imports (cif) Rs m9,56714,050 68.1%   
Fx inflow Rs m22,00475,405 29.2%   
Fx outflow Rs m11,74927,115 43.3%   
Net fx Rs m10,25548,290 21.2%   
CASH FLOW
From Operations Rs m8,02640,476 19.8%  
From Investments Rs m-1,744-19,421 9.0%  
From Financial Activity Rs m-4,447-17,009 26.1%  
Net Cashflow Rs m1,8344,046 45.3%  

Share Holding

Indian Promoters % 45.6 25.5 178.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 5.4 161.1%  
FIIs % 21.2 35.3 60.1%  
ADR/GDR % 0.0 18.5 -  
Free float % 21.1 15.3 137.9%  
Shareholders   23,815 75,885 31.4%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Dr Reddy's: Good show but challenges persist (Quarterly Results Update - Detailed)

Nov 16, 2015

Dr Reddy's has announced its 2QFY16 results. The company has reported 11.2% YoY growth in sales and 25.7% YoY growth in net profits. Here is our analysis of the results.

Dr Reddy's: Good show but challenges persist (Quarterly Results Update - Detailed)

Nov 16, 2015

Dr Reddy's has announced its 2QFY16 results. The company has reported 11.2% YoY growth in sales and 25.7% YoY growth in net profits. Here is our analysis of the results.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 21, 2017 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - ALEMBIC LTD COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS